Tags : Develop

Pharma

AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies

Shots: The companies collaborated to research, develop & commercialize small molecules directed against the GPR75 target with the potential to treat obesity and related co-morbidities The collaboration builds on the findings from the Regeneron Genetics Center of rare genetic mutations in the GPR75 gene associated with protection against obesity and on early joint research initiated […]Read More

Biotech

Skyhawk Collaborate with Aragen to Develop Novel Small Molecule Therapeutics

Shots: Skyhawk collaborated with Aragen for the development of small molecule therapeutics that correct RNA expression Under the collaboration, Skyhawk will get multiple discovery chemistry and biology service solutions from Aragen The alliance focuses to accelerate Skyhawk’s research pipeline. Aragen’s research expertise will help Skyhawk to advance the development of its novel small molecule therapeutics […]Read More

Biotech

Arrowhead Signs a License Agreement with Horizon to Develop siRNA

Shots: Arrowhead to receive $40M up front and is eligible to receive ~$660M as potential development, regulatory & commercial milestones, and is further eligible to receive royalties on net product sales Horizon to receive a WW exclusive license for ARO-XDH targeting XDH and will be wholly responsible for clinical development and commercialization of the therapy […]Read More

Biotech

Kite Enter into a Partnership with Shoreline Biosciences to Develop

Shots: Shoreline is eligible to receive ~$2.3B including upfront, development and commercialization milestones and additional payments along with royalties. The agreement follows Kite’s investment in Shoreline’s recent Series A financing The collaboration will utilize Shoreline’s iPSC differentiation and genetic reprogramming with Kite’s cell therapy to develop novel allogeneic therapies for hematologic malignancies Initially, the collaboration […]Read More

Biotech

MacroGenics Signs a License Agreement with Zai Lab to Develop

Shots: MacroGenics receives initial consideration of $55M, including ~$25M up front, $30M as an equity investment in common stock at $31.30/ share & is eligible to receive ~$1.4B as a milestone for 4 programs along with royalties in Zai Lab’s territories Zai lab gets rights to obtain DART & TRIDENT platforms to expand oncology portfolio […]Read More

Pharma

Verona Pharma Signs $219M Agreement with Nuance Pharma to Develop

Shots: Verona Pharma to receive $40M including $25M upfront cash and $15M equity interest in Nuance Biotech, and is eligible to receive ~$179M in milestones along with royalties on net sales in Greater China (mainland China, Taiwan, Hong Kong and Macau) Verona Pharma granted Nuance Pharma exclusive right to develop & commercialize ensifentrine in Greater […]Read More